Original Article IL1RAP as a surface marker for ….pdfVIP

Int J Clin Exp Med 2014;7(12):4787-4798 /ISSN:1940-5901/IJCEM0002720 Original Article IL1RAP as a surface marker for leukemia stem cells is related to clinical phase of chronic myeloid leukemia patients 1,2,3* 1* 1 1,2,3 3 3 3 3 Kai Zhao , Ling-Ling Yin , Dong-Mei Zhao , Bin Pan , Wei Chen , Jiang Cao , Hai Cheng , Zhen-Yu Li , 3 3 1,2,3 1,2,3 De-Peng Li , Wei Sang , Ling-Yu Zeng , Kai-Lin Xu 1Blood Diseases Institute, Xuzhou Medical College, No. 84 West Huaihai Road, Xuzhou 221002, Jiangsu, China; 2Key Laboratory of Bone Marrow Stem Cell, No. 84 West Huaihai Road, Xuzhou 221002, Jiangsu Province, China; 3Department of Hematology, The Affiliated Hospital of Xuzhou Medical College, No. 99 West Huaihai Road, Xuzhou 221002, Jiangsu, China. *Equal contributors. Received September 22, 2014; Accepted November 25, 2014; Epub December 15, 2014; Published December 30, 2014 Abstract: Chronic myeloid leukemia (CML) is a clonal disease from hematopoietic stem cells. Surviving leukemia stem cells (LSCs) and progenitor cells are a potential source for CML relapse and progression. Recent data reported that IL-1 receptor accessory protein (IL1RAP) gene was differentially expressed in CML versus normal stem and progenitor cells. However, whether the level of IL1RAP is associated with clinical phases of CML, and correlations between IL1RAP expression and detections of diagnosis is still unclear. Here we demonstrated that IL1RAP was up- regulated in CD34+ and CD34+CD38- cells which highly enriched with stem cells. Furthermore, IL1RAP expression in CD34+CD38- cells was tightly consistent with the generation of BCR-ABL fusion gene and Philadelphia chromo- some. Importantly, we found that the level of IL1RAP increased with disease progression from chronic phase (CP) into accelerated phase (A